TREATMENT PLANNER
Scheduling injection appointments for VOCABRIA▼(cabotegravir) + REKAMBYS▼(rilpivirine) may be new for your patient and yourself. This treatment planner is designed to help you support your patients when planning appointments. You can print off a summary of the appointments for your patient to assist them in adhering to treatment visits. Please select one of the buttons to get started.
Stopping VOCABRIA + REKAMBYS injections[1]
If treatment is discontinued, it is essential to start alternative ARV therapy no later than two months after the final injections (or one month if after first initiation injections) in order to minimise the risk of resistance.[1]
If virologic failure is suspected, an alternative regimen should be adopted as soon as possible.
ARV=antiretroviral.
REKAMBYS (rilpivirine long acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
